PART1 destabilized by NOVA2 regulates blood-brain barrier permeability in endothelial cells via STAU1-mediated mRNA degradation

Gene. 2022 Mar 20:815:146164. doi: 10.1016/j.gene.2021.146164. Epub 2022 Jan 4.

Abstract

Blood-brain barrier dysfunction is recognized as a precursor of Alzheimer's disease development. Endothelial cells as structural basis of blood-brain barrier were observed tight junction failure in amyloid-β(1-42)-stimulated environment. In this study, we found NOVA2, PPP2R3A were down-regulated while PART1, p-NFκB-p65 were up-regulated in amyloid-β(1-42)-incubated endothelial cells. Knockdown of either NOVA2 or PPP2R3A and overexpression of PART1 all increased blood-brain barrier permeability. Lower blood-brain barrier permeability was observed in overexpression of NOVA2 and PPP2R3A and knockdown of PART1 and NFκB-p65. Same tendencies were found in the tight junction-related proteins expressions. Furthermore, overexpression and knockdown of NOVA2 and PART1 had no effect on cell viability. Mechanistically, NOVA2 overexpression was confirmed to reduce half-life of PART1. PART1 could destabilize PPP2R3A messenger RNA (mRNA) by interacting with STAU1. In addition, p-NFκB-p65 functioning as transcription factor reduced the expression of tight junction-related proteins, which was prompted by low protein level of PPP2R3A. Our study highlights the crucial role of NOVA2/PART1/PPP2R3A/p-NFκB-p65 pathway in amyloid-β(1-42)-incubated endothelial cells to modulating blood-brain barrier permeability through STAU1-mediated messenger RNA degradation, implying a potential mechanism of lncRNA and protein interaction in pathogenesis of Alzheimer's disease.

Keywords: Alzheimer’s disease; Blood-brain barrier permeability; Endothelial cells; NFκB; NOVA2; SMD pathway.

MeSH terms

  • Alzheimer Disease / metabolism
  • Alzheimer Disease / pathology
  • Amyloid beta-Peptides / pharmacokinetics
  • Blood-Brain Barrier / drug effects
  • Blood-Brain Barrier / physiology*
  • Cells, Cultured
  • Cytoskeletal Proteins / genetics
  • Cytoskeletal Proteins / metabolism*
  • Electric Impedance
  • Endothelial Cells
  • Gene Expression Regulation
  • Humans
  • Neuro-Oncological Ventral Antigen / genetics*
  • Neuro-Oncological Ventral Antigen / metabolism
  • Neuroglia
  • Peptide Fragments / pharmacokinetics
  • Protein Phosphatase 2 / genetics
  • Protein Phosphatase 2 / metabolism
  • Protein Stability
  • RNA Stability
  • RNA, Untranslated / genetics
  • RNA, Untranslated / metabolism*
  • RNA-Binding Proteins / genetics
  • RNA-Binding Proteins / metabolism*
  • Tight Junction Proteins / genetics
  • Tight Junction Proteins / metabolism
  • Transcription Factor RelA / genetics
  • Transcription Factor RelA / metabolism

Substances

  • Amyloid beta-Peptides
  • Cytoskeletal Proteins
  • NOVA2 protein, human
  • Neuro-Oncological Ventral Antigen
  • PART-1 RNA, human
  • Peptide Fragments
  • RNA, Untranslated
  • RNA-Binding Proteins
  • STAU1 protein, human
  • Tight Junction Proteins
  • Transcription Factor RelA
  • amyloid beta-protein (1-42)
  • PPP2R3A protein, human
  • Protein Phosphatase 2